Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

Novartis bolsters radioligand therapy pipeline with new licence agreement

Novartis bolsters radioligand therapy pipeline with new licence agreement We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. ... We believe working across multiple approaches is the key to reimagining cancer care,” said Susanne Schaffert, president, Novartis Oncology.

Novartis gains EU approval for relapsing MS drug Kesimpta

Novartis gains EU approval for relapsing MS drug Kesimpta The European Commission (EC) has approved Novartis’ Kesimpta for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease. ... According to Genmab, Kesimpta is the first B-cell therapy that can be self-administered at

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi Evrysdi becomes the third drug approved to treat the condition, following Biogen's Spinraza (nusinersen) and Novartis' Zolgensma (onasemnogene abeparvovec), and is the first that can be administered orally.

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease Isturisa was originally developed by Novartis, although Recordati licensed global rights from the company in July 2019 for $390m upfront in a deal that also included rights to Signifor and Signifor

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer Novartis’ investigational radioligand therapy 177Lu-PSMA-617 hit both primary endpoints in a phase 3 trial in patients with advanced prostate cancer. ... In a statement, Novartis said this therapeutic approach limits damage to the surrounding normal

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...